Hypertension Remission After Bariatric Surgery: A Comprehensive Review
Published on: 13 Aug 2025
Introduction
Hypertension (HTN), characterized by persistently elevated arterial blood pressure (BP), is one of the most prevalent chronic health conditions globally. Affecting approximately 1.4 billion people in 2019 with projections rising to 1.6 billion by 2025, hypertension significantly contributes to cardiovascular morbidity and mortality, including heart failure, atrial fibrillation, chronic kidney disease, and stroke. High body mass index (BMI) is a leading risk factor for hypertension, accounting for over 40% of hypertensive heart disease-related disability-adjusted life years (DALYs). Despite pharmacological and lifestyle interventions, hypertension often remains poorly controlled in patients with obesity, prompting increasing interest in bariatric surgery as a long-term management strategy.
Efficacy of Bariatric Surgery in Blood Pressure Control
Short- and Medium-Term Outcomes
Multiple randomized controlled trials (RCTs) and cohort studies consistently demonstrate that bariatric surgery yields superior reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to non-surgical interventions such as diet, medication, or lifestyle changes. For instance, an observational study involving 830 adults noted a decrease in SBP from 143.6 mmHg pre-surgery to 125.5 mmHg at 1 year, with DBP dropping from 89.5 mmHg to 75.4 mmHg over the same period. Meta-analyses pooling data from 19 RCTs with over 1,300 patients confirmed significant BP reductions post-surgery, with surgical patients being over four times more likely to achieve hypertension remission compared to non-surgical controls.
Long-Term Durability and Relapse
While short- and medium-term outcomes are promising, the durability of hypertension remission diminishes over time. Large cohort studies report that approximately 60% of bariatric surgery patients maintain remission at 5 years, but this advantage decreases, with nearly half experiencing relapse within this period. The Swedish Obese Subjects (SOS) study revealed remission rates fell from 34% at 2 years to 19% at 10 years post-surgery. Relapse rates underscore the necessity of continual monitoring and lifestyle modification to maintain blood pressure control.
Comparison of Bariatric Procedures
Two primary bariatric procedures are commonly performed: Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG). Comparative analyses reveal:
-
Gastric Bypass (RYGB): Demonstrates higher long-term hypertension remission rates. Systematic reviews report RYGB confers 26% higher remission at 5 years and 39% higher remission beyond 5 years compared to SG.
-
Sleeve Gastrectomy (SG): Shows comparable short-term remission rates to RYGB but a slightly higher risk of relapse in the long term in some studies.
Other surgical methods like One-Anastomosis Gastric Bypass (OAGB) have shown similar efficacy to SG in medium-term remission, suggesting that both can be effective options depending on patient-specific factors.
Definitions and Measurement Variability
The heterogeneity in defining hypertension remission complicates outcome comparisons. Common definitions include:
- Complete Remission: BP below 140/90 mmHg without antihypertensive medications.
-
Partial Remission: Significant reduction in BP and medication use, but BP may remain above target levels.
The 2017 ACC/AHA guidelines introduced a lower threshold for hypertension (130/80 mmHg), which some studies adopted, leading to stricter remission criteria. Additionally, measurement techniques vary between office-based BP readings and 24-hour ambulatory BP monitoring, further contributing to differing reported remission rates.
Pathophysiological Mechanisms Underlying Hypertension Remission
Bariatric surgery triggers complex metabolic, hormonal, and vascular changes that contribute to blood pressure improvement:
Gut Microbiota Modulation
Postoperative shifts in gut microbiota composition, including increased populations of Akkermansia muciniphila, Bacteroides, Prevotella, and Faecalibacterium prausnitzii, enhance gut barrier function, reduce systemic inflammation, and produce short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. These SCFAs engage G-protein-coupled receptors (GPCRs) on vascular cells, promoting vasodilation and attenuating sympathetic nervous system activity, ultimately lowering BP.
Renal Function Improvement
Bariatric surgery alleviates glomerular hyperfiltration and reduces renal oxidative stress, enhancing kidney function. Increased natriuresis, driven by decreased renin-angiotensin-aldosterone system (RAAS) activity, reduces fluid retention and BP. Enhanced renal oxygenation and reduced oxidative stress further protect renal health.
Endothelial and Vascular Remodeling
Improvements in endothelial function result from reduced oxidative stress, restored nitric oxide (NO) bioavailability, and decreased vascular stiffness. Bariatric surgery reduces arterial strain and inflammation by mitigating the effects of advanced glycation end products (AGEs). Enhanced activity of endothelial progenitor cells accelerates vascular repair. Changes in lipid profiles—elevated HDL and reduced LDL—alongside decreased pro-inflammatory cytokines (TNF-α, IL-6) and increased vagal tone, collectively improve vascular health.
Hormonal and Adipose Tissue Changes
Post-surgery hormonal shifts include decreased leptin, increased adiponectin, elevated glucagon-like peptide-1 (GLP-1), and fibroblast growth factor 21 (FGF21), which improve insulin sensitivity and reduce inflammation. Activation of brown adipose tissue (BAT) enhances thermogenesis and metabolic health via increased mitochondrial uncoupling protein 1 (UCP1). This BAT activation and improved adipokine balance contribute to reduced hypertension and cardiovascular risk.
Patient Selection and Predictors of Remission
The likelihood of hypertension remission depends on several clinical and demographic factors:
-
Shorter Duration of Hypertension: Patients with HTN history less than 10 years have higher remission rates; each additional year reduces remission likelihood by approximately 15%.
-
Fewer Preoperative Antihypertensive Medications: Use of ≤1 medication predicts better remission and lower recurrence.
-
Greater Postoperative Weight Loss: Higher excess weight loss (%EWL) and total weight loss (%TWL) correlate strongly with remission.
-
Younger Age: Younger patients tend to have more favorable outcomes.
-
Metabolic Comorbidities: Presence of type 2 diabetes mellitus (T2DM) and hyperuricemia can influence remission positively.
-
Visceral Fat Area (VFA): Smaller VFA is associated with higher remission and lower recurrence.
Early surgical intervention is advocated to maximize remission and reduce relapse risk.
Pharmacological Management After Surgery
Despite significant remission rates, many patients require ongoing antihypertensive therapy post-bariatric surgery. Tailored pharmacological strategies are essential:
-
Renin-Angiotensin System (RAS) Inhibitors: ACE inhibitors and angiotensin receptor blockers (ARBs) are preferred, especially in patients with diabetes or proteinuric kidney disease, due to their cardiometabolic benefits.
-
Diuretics: Used cautiously due to dehydration risk; tapering is advised postoperatively.
-
Beta-Blockers: Often reduced or avoided unless indicated, as weight loss improves resting heart rate.
-
Calcium Channel Blockers: Suitable for additional BP control but require monitoring for edema.
-
Mineralocorticoid Receptor Antagonists: Effective in resistant hypertension or hyperaldosteronism.
Up to 30–50% of patients may discontinue antihypertensive medications within 12 months post-surgery, particularly those on fewer preoperative drugs.
Knowledge Gaps and Future Directions
Several areas require further investigation to optimize hypertension management after bariatric surgery:
- Mechanisms of Remission vs. Recurrence: Deeper understanding of metabolic versus non-metabolic hypertension remission pathways is needed.
- Role of Revisional Surgery: Effects of secondary procedures on blood pressure control warrant exploration.
- Impact on Non-Metabolic Hypertension: Benefits for genetically predisposed or primary aldosteronism-related hypertension remain underexplored.
- Adjunct Pharmacotherapy: Combining pharmacological obesity treatments (e.g., liraglutide, semaglutide) with surgery to enhance remission rates merits systematic evaluation.
-
Standardization: Uniform definitions for remission and relapse would improve comparability and clinical guidance.
Conclusions
Bariatric surgery represents a transformative intervention for hypertension management in obese patients, delivering superior short- and medium-term blood pressure reductions and remission rates compared to non-surgical treatments. Gastric bypass procedures generally outperform sleeve gastrectomy in long-term hypertension remission. Patient factors such as hypertension duration, medication burden, weight loss magnitude, and age are critical predictors of outcomes. The surgery induces multifaceted metabolic, hormonal, vascular, and microbiota-related changes that collectively contribute to improved cardiovascular health. Sustained follow-up, individualised pharmacological management, and further research into underlying mechanisms and adjunct therapies are essential to maximise long-term benefits and minimise relapse.
SOURCE/READ FULL ARTICLE: 10.1007/s11886-025-02280-1
LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT
